Hyperinsulinemia and Gastric Cancer represent a critical intersection between metabolic dysfunction and oncogenesis. For over two decades, extensive research has highlighted how elevated insulin levels act as a potent growth factor for tumor cells. Specifically, this metabolic state provides the necessary stimuli and chemical energy for malignant cells to thrive and survive. This review synthesizes current evidence to explore the biochemical pathways involved and evaluates clinical management strategies to mitigate these risks for patients.

Biochemical Pathways in Hyperinsulinemia and Gastric Cancer

The link between these conditions involves the direct activation of the PI3K/AKT and MAPK/ERK signaling cascades. These pathways are frequently dysregulated in gastric cancer through the overexpression of insulin receptor isoform A. Furthermore, oncogenic mutations in key regulatory proteins amplify these signals significantly. Consequently, the tumor microenvironment experiences increased cell proliferation, enhanced angiogenesis, and a heightened resistance to standard therapies. These changes make the cancer more aggressive and harder to treat.

Additionally, the intricate crosstalk between these cascades and other pathways, such as NF-kB and JAK/STAT, fosters a pro-inflammatory milieu. This inflammatory environment promotes a mesenchymal phenotype and drives tumor microenvironment remodeling. Therefore, clinicians must recognize hyperinsulinemia not merely as a diabetic precursor, but as a direct biochemical driver of gastric malignancy progression. Addressing insulin resistance early may be vital in preventing cancer development.

The Protective Potential of Metformin

Management strategies focus on modulating these metabolic stimuli through both dietary interventions and pharmacological approaches. Notably, recent clinical evidence suggests that metformin significantly alters the course of the disease. A comprehensive meta-analysis indicates that metformin use correlates strongly with a reduced risk of gastric cancer, showing a Hazard Ratio (HR) of 0.67. Moreover, patients taking metformin often experience better clinical outcomes, including lower recurrence rates (HR: 0.61). These findings emphasize the clinical importance of insulin-sensitizing therapies in modern oncology care.

FAQs

What is the link between hyperinsulinemia and gastric cancer?

Hyperinsulinemia promotes gastric cancer by activating specific signaling pathways like PI3K/AKT and MAPK/ERK. These pathways increase cell proliferation and tumor survival by providing metabolic energy and growth signals to malignant cells.

How does metformin help in gastric cancer management?

Metformin significantly reduces the risk of developing gastric cancer and lowers the likelihood of recurrence after treatment. It achieves this by sensitizing tissues to insulin and inhibiting the oncogenic signaling pathways that drive tumor growth.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional diagnosis or treatment. Clinicians should use their professional judgment and consider individual patient factors. Refer to the latest local and national guidelines for clinical practice.

References

Laurenziello P et al. A sweet danger: the silent link between hyperinsulinemia and gastric cancer. Mol Cancer. 2026 May 25. doi: 10.1186/s12943-026-02693-8. PMID: 42185920.

Tseng CH. Metformin and gastric cancer risk in patients with type 2 diabetes mellitus. World J Gastroenterol. 2016;22(4):1666-1673.

Wang H et al. Hyperinsulinemia and its role in cancer development and progression. Endocr-Relat Cancer. 2020.